Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department: A Randomized Non-inferiority Trial

NCT07816302 is registered in ClinicalTrials.gov with Tehran University of Medical Sciences as lead sponsor.

NCT NCT07816302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07816302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department: A Randomized Non-inferiority Trial
Lead sponsor
Tehran University of Medical Sciences
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 10, 2026
Completion date
May 1, 2027
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

intranasal drug administration, ketorolac, pain